Eminyakeni yamuva nje, ngesidingo esikhulayo sabathengi sezithako zobuhle bemvelo nezisebenza kahle, ukusetshenziswa kwama-peptide e-bioactive emkhakheni wezimonyo kudonse ukunaka okukhulu. Phakathi kwazo,I-Myristoyl Pentapeptide-17, evame ukubizwa ngokuthi "i-eyelash peptide", isibe isithako esiyinhloko semikhiqizo yokunakekelwa kwe-eyelashes ngenxa yomphumela wayo oyingqayizivele wokukhuthaza ukukhula kwezinwele, futhi isheshe yavusa izingxoxo ezishisayo ngaphakathi nangaphandle kwemboni.
● Ukusebenza kahle: Yenza kusebenze izakhi zofuzo ze-keratin futhi ikhuthaze ngokuphawulekayo ukukhula kwezinkophe
I-Myristoyl pentapeptide-17i-pentapeptide yokwenziwa indlela yayo yokusebenza igxile ezixhumanisini ezibalulekile zokuthuthukiswa kwefollicle yezinwele:
1.Vuselela izakhi zofuzo ze-keratin: Ngokukhuthaza ngokuqondile amangqamuzana ezinwele ze-papilla, kuthuthukisa ukubonakaliswa kwezakhi zofuzo ze-keratin, ngaleyo ndlela kukhuthaze ukwakheka kwe-keratin kuma-eyelashes, amashiya nezinwele, okwenza izinwele zibe mkhulu futhi zibe nzima.
I-2.Yandisa isikhathi sokukhula kwezinwele: Ucwaningo lwezokwelapha luye lwabonisa ukuthi ngemva kwamasonto amabili okusetshenziswa okuqhubekayo kwesisombululo sokunakekelwa esiqukethe i-10% yalesi sithako, ubude nobuningi be-eyelashes bunganyuswa ngo-23%, futhi umphumela ungafinyelela ku-71% ngemva kwamasonto ayisithupha.
3.Ukuphepha okuphezulu: Uma kuqhathaniswa nokucasula kwamakhemikhali endabuko, izithako ze-peptide azinayo imiphumela emibi futhi zifanele izindawo ezibucayi njengamajwabu amehlo.
●Uhlelo lokusebenza: Ukungena okuphelele kusuka kolayini bomsebenzi kuya ezimakethe ezinkulu
I-Myristoyl pentapeptide-17isetshenziswe kabanzi emikhiqizweni yobuhle eyahlukene futhi isiyisihluthulelo somncintiswano wokuhlukanisa umkhiqizo:
Imikhiqizo Yokunakekelwa Kwezinkophe
1.I-serum yokukhula kwezinkophe: Njengesithako esisebenzayo esiyinhloko, inani elinconyiwe lokwengezwa ngu-3% -10%, futhi yengezwa kufomula ngesigaba samanzi esinezinga lokushisa eliphansi ukuze kuqinisekiswe ukuzinza.
2.I-Mascara: Ihlanganiswe nama-ejenti enza ifilimu kanye nezithako ezinomsoco, inokubili imiphumela esheshayo yokwenza kanye nemisebenzi yokunakekela yesikhathi eside.
Ukunakekelwa Kwezinwele Nemikhiqizo Yamashiya
Kunwetshwe ezigabeni ezifana ne-shampoo namapensela amashiya ukusiza ukuthuthukisa inkinga yezinwele ezingandile.
Amafomu Esilinganiso Esihlukene
Abahlinzeki bahlinzeka ngezindlela ezimbili zeI-Myristoyl pentapeptide-17impushana (1g-100g) kanye noketshezi (20ml-5kg) ukuhlangabezana nezidingo zefomula ezahlukene.
● I-Industry Dynamics: ukunwetshwa kwe-supply chain kanye nokuqanjwa kabusha kwezobuchwepheshe
Abakhiqizi basheshisa isakhiwo:
Izinkampani eziningi emhlabeni wonke ziye zazuza ukukhiqizwa okukhulu kweI-Myristoyl pentapeptide-17, nobumsulwa bomkhiqizo bufinyelela ku-97% -98%. Abakhiqizi abaningi baye basungula izixazululo ze-"eyelash peptide", ezigxile ekusebenzisaneni okuphezulu nokuzinza kwezinga lokushisa eliphansi futhi zamukelwe yimikhiqizo eminingi.
Ucwaningo lwezokwelapha lukhuthaza ukuthuthukiswa okujwayelekile:
Izikhungo zocwaningo ekhaya nasemazweni angaphandle zijulisa ukuhlola kwazo indlela yokusebenza kwayo, njengokwenza ngcono ukunikezwa kwezakhi zezinhlayiya zezinwele ngokugqugquzela ukulethwa kwezici zokukhula.
Amathemba emakethe abanzi:
Ngokwezibikezelo zezimboni, imakethe yomhlaba wonke yokunakekelwa kwe-elash izodlula ama-US $ 5 billion ngo-2025, futhi izithako ze-peptide ze-bioactive kulindeleke ukuthi ziphendule ngaphezu kwama-30%.
●I-Outlook Yesikhathi esizayo
Ukunyuka kweI-myristoyl pentapeptide-17iphawula ukuguqulwa kwemboni yezimonyo isuka “ekumbozeni nasekulungiseni” iye “kukulungisa izinto eziphilayo”. Ngokuphindaphindwa kobuchwepheshe kanye nokujula kwemfundo yabathengi, izindawo zayo zokusebenza zinganwetshwa ngokuqhubekayo zibe zezokwelapha nezobuhle ngemva kokulungisa, ukwelashwa kokulahlekelwa izinwele nezinye izimo, zibe isithako esilinganiselwe sokusungula ubuchwepheshe bobuhle.
●NewGREEN SupplyI-Myristoyl Pentapeptide-17Impushana
Isikhathi sokuthumela: Mar-21-2025



